Adamas earns milestone from Actavis

• Adamas Pharmaceuticals (ADMS) receives a $30M milestone payment from Actavis (ACT) subsidiary Forest Laboratories for the FDA clearance of Namzaric (memantine hydrochloride/donepezil hydrochloride) for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
• Forest submitted the NDA in February 2014.
• Previously: FDA clears Adamas Alzheimer's drug (Dec. 24, 2014)